A population study of clinical trial accrual for women and minorities in neuro-oncology following the NIH Revitalization Act. Issue 8 (6th January 2022)

• Record Type: Journal Article
• Authors: Reihl, Sheantel J; Patil, Nirav; Morshed, Ramin A; Mehari, Mulki; Aabedi, Alexander; Chukwueke, Ugonma N; Porter, Alyx B; Fontil, Valy; Cioffi, Gino; Waite, Kristin; Kruchko, Carol; Ostrom, Quinn; Barnholtz-Sloan, Jill; Hervey-Jumper, Shawn L
• Is Part Of: Neuro-oncology. Volume 24:Issue 8(2022)
• Page Start: 1341
• Page End: 1349
• Publication Date: 2022-01-06
• Subjects: clinical trials -- clinical trial accrual -- disparities -- glioma; Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noac011
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: Background: The NIH Revitalization Act, implemented 29 years ago, set to improve the representation of women and minorities in clinical trials. In this study, we investigate progress made in all phase therapeutic clinical trials for neuroepithelial CNS tumors stratified by demographic-specific age-adjusted disease incidence and mortality. Additionally, we identify workforce characteristics associated with clinical trials meeting established accrual benchmarks. Methods: Registry study of published clinical trials for World Health Organization defined neuroepithelial CNS tumors between January 2000 and December 2019. Study participants were obtained from PubMed and ClinicalTrials.gov. Population-based data originated from the CBTRUS for incidence analyses. SEER-18 Incidence-Based Mortality data was used for mortality analysis. Descriptive statistics, Fisher exact, and χ 2 tests were used for data analysis. Results: Among 662 published clinical trials representing 49 907 participants, 62.5% of participants were men and 37.5% women ( P < .0001) representing a mortality specific over-accrual for men ( P = .001). Whites, Asians, Blacks, and Hispanics represented 91.7%, 1.5%, 2.6%, and 1.7% of trial participants. Compared with mortality, Blacks (47% of expected mortality, P = .008), Hispanics (17% of expected mortality, P < .001) and Asians (33% of expected mortality, P < .001) were underrepresented compared with Whites (114% of expected mortality, P < .001). Clinical trials meeting accrual benchmarks for race included minority authorship. Conclusions: Following the Revitalization Act, minorities and women remain underrepresented in therapeutic clinical trials for neuroepithelial tumors, relative to disease incidence and mortality. Study accrual has improved with time. This study provides a framework for clinical trial accrual efforts and offers guidance regarding workforce considerations associated with enrollment of underserved patients.